Document is current
Any future updates will be listed below
-
Authors
Mostafa, Ahmed https://orcid.org/0000-0002-2878-5714
Ye, Chengjin
Barre, Ramya S.
Shivanna, Vinay
Meredith, Reagan
Platt, Roy N.
Escobedo, Ruby A.
Bayoumi, Mahmoud
Castro, Esteban M.
Jackson, Nathaniel
Cupic, Anastasija
Nogales, Aitor
Anderson, Timothy J. C.
García-Sastre, Adolfo
Martinez-Sobrido, Luis https://orcid.org/0000-0001-7084-0804
- License Information
-
More Information
Article History
Received: 29 March 2025
Accepted: 24 June 2025
First Online: 12 July 2025
Competing interests
: The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca and NovavaxA.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. All other authors declare no commercial or financial conflict of interest.
